{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:08:49Z","timestamp":1785928129373,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.intimp.2021.107985","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T04:30:29Z","timestamp":1628742629000},"page":"107985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: Results of two randomized, double-blind, placebo-controlled studies"],"prefix":"10.1016","volume":"99","author":[{"given":"Pierre-Fran\u00e7ois","family":"Clot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WeiHong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaozong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2021.107985_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"1","key":"10.1016\/j.intimp.2021.107985_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107985_b0015","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jdv.15618","article-title":"Phenotypic analysis of atopic dermatitis in children aged 1\u201312 months: elaboration of novel diagnostic criteria for infants in China and estimation of prevalence","volume":"33","author":"Guo","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2021.107985_b0020","doi-asserted-by":"crossref","first-page":"29751","DOI":"10.1038\/srep29751","article-title":"Prevalence of atopic dermatitis in Chinese children aged 1\u20137 ys","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2021.107985_b0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2340\/00015555-3104","article-title":"The prevalence of atopic dermatitis and chronic spontaneous urticaria are associated with parental socioeconomic status in adolescents in China","volume":"99","author":"Xiao","year":"2019","journal-title":"Acta. Derm. Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107985_b0030","doi-asserted-by":"crossref","DOI":"10.5620\/eaht.2020012","article-title":"Age-period-cohort analysis of asthma, allergic rhinitis, and atopic dermatitis prevalence in Japan","volume":"35","author":"Okui","year":"2020","journal-title":"Environ. Anal. Health Toxicol."},{"issue":"5","key":"10.1016\/j.intimp.2021.107985_b0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"14","key":"10.1016\/j.intimp.2021.107985_b0040","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"14","key":"10.1016\/j.intimp.2021.107985_b0045","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"6","key":"10.1016\/j.intimp.2021.107985_b0050","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2 AD ADOL, and CHRONOS","volume":"82","author":"Silverberg","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10086","key":"10.1016\/j.intimp.2021.107985_b0055","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"10013","key":"10.1016\/j.intimp.2021.107985_b0060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2021.107985_b0065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-019-1065-3","article-title":"Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials","volume":"20","author":"Xiong","year":"2019","journal-title":"Respir. Res."},{"issue":"10209","key":"10.1016\/j.intimp.2021.107985_b0070","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2021.107985_b0075","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2021.107985_b0080","unstructured":"Y. Zhao, L. Wu, Q. Lu, X. Gao, X. Zhu, X. Yao, et al., Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis in Chinese adults: A multicenter, randomised, double-blind, placebo-controlled, phase 3 trial. ISAD (2021) International Symposium on Atopic Dermatitis \u2013 11th Georg Rajka International Symposium; April 19\u201320, 2021."},{"key":"10.1016\/j.intimp.2021.107985_b0085","unstructured":"Sanofi, Dupixent\u00ae (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis, 2020. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2020\/2020-06-19-13-30-00. (Accessed September 7, 2020)."},{"issue":"10039","key":"10.1016\/j.intimp.2021.107985_b0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.intimp.2021.107985_b0095","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"issue":"24","key":"10.1016\/j.intimp.2021.107985_b0100","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2021.107985_b0105","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cpdd.798","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of dupilumab in healthy adult subjects","volume":"9","author":"Li","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"1","key":"10.1016\/j.intimp.2021.107985_b0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107985_b0115","first-page":"804","article-title":"Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials","volume":"18","author":"Alexis","year":"2019","journal-title":"J. Drugs Dermatol."},{"issue":"11","key":"10.1016\/j.intimp.2021.107985_b0120","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/psp4.12136","article-title":"Exploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL-4R\u03b1, in atopic dermatitis patients and normal volunteers","volume":"5","author":"Kovalenko","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.intimp.2021.107985_b0125","unstructured":"Regeneron Pharmaceuticals, Inc, Dupixent\u00ae (dupilumab) injection, for subcutaneous use, 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761055s007lbl.pdf. (Accessed March 22, 2021)."},{"issue":"1","key":"10.1016\/j.intimp.2021.107985_b0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjd.18476","article-title":"Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension","volume":"182","author":"Cork","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107985_b0135","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.16928","article-title":"A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy","volume":"35","author":"Paller","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921006214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921006214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T20:14:05Z","timestamp":1730837645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921006214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":27,"alternative-id":["S1567576921006214"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107985","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: Results of two randomized, double-blind, placebo-controlled studies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sanofi & Regeneron Pharmaceuticals, Inc. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107985"}}